ChemoCentryx, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The following company report cites that the company, “Inhibition of CCR2 in various animal models has been shown to be beneficial in models of acute kidney injury, post myocardial infarction reperfusion injury, vascular endothelial injury, and hepatosteatosis (fatty liver), among others.” (Page 5) Read the full document.
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company. The company focuses on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. Its pipeline consist of CCX168 avacopan, CCX140: Diabetic Nephropathy, CCX872: Pancreatic Cancer, CCR1, CCR4, CCR5, CCR6, CXCR2, Vercirnon: IBD: crohn’s disease, CCX507: IBD: Ulcerative Colitis and CCR6: Psoriasis. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA. [Source: MarketWatch]
Company Website: http://www.chemocentryx.com